Abstract

Bicuspid aortic valve (BAV) disease is the most common congenital heart disease and the main etiology of aortic stenosis (AS) in young adults. Recent studies have suggested that transcatheter aortic valve replacement (TAVR) in bicuspid aortic stenosis (BAS) have comparable clinical outcomes to surgical aortic valve replacement. The US FDA recently approved TAVR for BAS. The expansion of TAVR into patients at lower surgical risk is a current topic of interest. We aimed to investigate the trends in baseline characteristics in patients with BAS undergoing TAVR.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.